Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Enzymatic Treatment for Postoperative Nasal Fibrosis After Rhinoplasty

11. november 2026 oppdatert av: Research Inc

A Fixed-Sequence Crossover Clinical Trial Evaluating Enzymatic Treatment for Mild-to-Moderate Postoperative Nasal Fibrosis After Rhinoplasty

This single-arm, fixed-sequence clinical trial will evaluate an enzymatic preparation for mild-to-moderate postoperative fibrosis of the nasal soft-tissue envelope after rhinoplasty. Each participant will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed, after which the participant will receive a 3-mL enzymatic preparation in the same affected area. A second clinical assessment and ultrasound examination will be performed 2 weeks after the enzymatic treatment. Changes during the saline and enzymatic treatment periods will be compared within each participant.

Studieoversikt

Detaljert beskrivelse

Adults with mild-to-moderate fibrosis of the nasal soft-tissue envelope after rhinoplasty will receive two interventions in a fixed sequence. During Period 1, 3 mL of sterile saline will be injected into the affected nasal area. At 2 weeks, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed. The enzymatic preparation will then be injected into the same affected area. It will contain recombinant lipase, collagenase, and hyaluronidase and will be prepared by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline, for a total volume of 3 mL. Two weeks after the enzymatic treatment, clinical assessment and ultrasound, including elastography, will be repeated. All participants will receive saline first and the enzymatic preparation second.

Studietype

Intervensjonell

Registrering (Antatt)

80

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Bogota D.C.
      • Bogotá, Bogota D.C., Colombia, 110121
        • Rekruttering
        • NUARA
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 18 years or older. History of rhinoplasty performed at least 3 months before enrollment. Complete healing of the surgical wounds at enrollment. Mild-to-moderate fibrosis of the nasal soft-tissue envelope in an identifiable affected area, diagnosed by clinical examination and documented by baseline high-resolution nasal ultrasonography.

Ability and willingness to provide written informed consent. Ability and willingness to complete the study assessments and follow-up visits.

Exclusion Criteria:

  • Severe nasal fibrosis or deformity requiring surgical correction or urgent treatment.

Active infection, open wound, ulceration, or tissue necrosis in the proposed injection area.

Previous injection or other treatment specifically for nasal fibrosis Known hypersensitivity to any component of the enzymatic preparation or to sterile saline.

Pregnancy or breastfeeding. Any medical condition that, in the investigator's judgment, makes study injections unsafe or prevents reliable completion of study assessments.

Inability to provide informed consent or comply with study procedures.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Fixed Sequence: Saline Followed by Enzymatic Treatment

All participants will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, after clinical assessment and ultrasound, they will receive 3 mL of a recombinant enzymatic preparation containing lipase, collagenase, and hyaluronidase, injected into the same affected area. The enzymatic preparation will be reconstituted with 1.5 mL of high-molecular-weight hyaluronic acid, followed approximately 5 minutes later by 1.5 mL of sterile saline. Final ultrasound and clinical assessment will be performed 2 weeks after the enzymatic treatment.

A total volume of 3 mL of sterile saline injected into the affected nasal area once at the beginning of the study.

A total volume of 3 mL containing recombinant lipase, collagenase, and hyaluronidase, injected into the affected nasal area 2 weeks after the saline injection. The preparation will be made by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference in change in nasal soft-tissue thickness between the saline and enzymatic treatment periods
Tidsramme: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

High-resolution nasal ultrasonography will be used to measure soft-tissue thickness at the prespecified affected area. Measurements will be obtained before saline treatment, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. Thickness will be recorded in millimeters.

Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference in change in nasal soft-tissue elastography measurements between treatment
Tidsramme: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

Elastography will be recorded at the prespecified affected area at baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. The elastography parameter and units reported by the ultrasound system will be specified in the study protocol.

Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
Change in structural characteristics of the nasal soft-tissue envelope
Tidsramme: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

Structural characteristics of the previously operated nasal soft-tissue envelope at the affected area will be assessed by high-resolution nasal ultrasonography at each study assessment.

Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
Treatment-emergent adverse events
Tidsramme: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

Adverse events reported or observed after saline and enzymatic injections, including local pain, swelling, erythema, skin changes, infection, tissue injury, or other adverse events.

Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juni 2026

Primær fullføring (Faktiske)

1. november 2026

Studiet fullført (Antatt)

31. desember 2026

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

non considered in the patient informed consent

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere